Pre-meeting Session:
PW5. HCV Treatment Options: Opportunities for the ID Practice $
Wednesday, October 2, 2013: 8:00 AM-12:00 PM
Room: The Moscone Center: 102 (Gateway Ballroom)
Co-organized with the IDSA Clinical Affairs Committee and Hepatitis C Task Force

Learning Objectives:

Case presentations will be used throughout this workshop.  At the conclusion of this session, participants will be able to:

  • discuss new screening guidelines and non-invasive modalities for assessment of liver damage
  • identify the latest drugs approved for both HCV mono-infection and HCV/HIV co-infection along with the treatment and management guidelines for both naïve, and experienced patients
  • implement strategies to optimize office management for HCV patients
  • identify medical problems common to HCV patients
  • outline the basics of care of the compensated cirrhotic patients

Target Audience: members-in-training, infectious diseases physicians, HIV clinicians, fellows, clinicians

Tracks: Adult ID

Pre-Meeting Workshop Panelists:  Eliot W. Godofsky, MD, Bach and Godofsky and David Thomas, MD, MPH, FIDSA, Johns Hopkins University

Pre-Meeting Workshop Moderators:  Eliot W. Godofsky, MD, Bach and Godofsky and David Thomas, MD, MPH, FIDSA, Johns Hopkins University

Presentations:

8:00 AM
Workshop Handouts
Albert Bond

8:01 AM

8:30 AM
New Modalities in Assessment of Liver Damage
David Thomas, MD, MPH, FIDSA

8:55 AM
HCV Therapy Today
Susanna Naggie, MD

9:40 AM

9:50 AM
HCV Therapy Tomorrow
Mark Sulkowski, MD

10:35 AM

11:00 AM
Medical Care of the HCV Patient
Ronald Wasserman, MD

11:25 AM
Clinical Cases
Eliot W. Godofsky, MD

11:40 AM
Clinical Cases
David Thomas, MD, MPH, FIDSA

11:55 AM
Q&A

CME Credits: Maximum of 3.75 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 4.0 application-based contact hours (0.4 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-077-L01-P

Disclosures:

E. W. Godofsky, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator, Research support
Boeringer-Ingelheim: Investigator, Research support
Vertex Pharmaceutical: Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
Gilead Pharmaceutical: Investigator, Research support
Novartis: Investigator, Research support
Genentech: Scientific Advisor, Consulting fee
Anadys Pharmaceutical: Investigator, Research support
Idenix Pharmaceutical: Investigator, Research support
Janssen Pharmaceutical: Investigator, Research support

D. Thomas, Sandhill: Scientific Advisor, Consulting fee
Gilead: Consultant and Grant Investigator, Consulting fee and Educational grant
Merck: Grant Investigator, Grant recipient

E. W. Godofsky, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator, Research support
Boeringer-Ingelheim: Investigator, Research support
Vertex Pharmaceutical: Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
Gilead Pharmaceutical: Investigator, Research support
Novartis: Investigator, Research support
Genentech: Scientific Advisor, Consulting fee
Anadys Pharmaceutical: Investigator, Research support
Idenix Pharmaceutical: Investigator, Research support
Janssen Pharmaceutical: Investigator, Research support

D. Thomas, Sandhill: Scientific Advisor, Consulting fee
Gilead: Consultant and Grant Investigator, Consulting fee and Educational grant
Merck: Grant Investigator, Grant recipient

T. G. Slama, None

E. W. Godofsky, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator, Research support
Boeringer-Ingelheim: Investigator, Research support
Vertex Pharmaceutical: Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
Gilead Pharmaceutical: Investigator, Research support
Novartis: Investigator, Research support
Genentech: Scientific Advisor, Consulting fee
Anadys Pharmaceutical: Investigator, Research support
Idenix Pharmaceutical: Investigator, Research support
Janssen Pharmaceutical: Investigator, Research support

D. Thomas, Sandhill: Scientific Advisor, Consulting fee
Gilead: Consultant and Grant Investigator, Consulting fee and Educational grant
Merck: Grant Investigator, Grant recipient

S. Naggie, Gilead Sciences: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient

M. Sulkowski, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research grant
BIPI: Investigator, Research Contractor and Scientific Advisor, Consulting fee and Research grant
BMS: Investigator and Scientific Advisor, Consulting fee and Research grant
Gilead : Investigator and Scientific Advisor, Consulting fee and Research grant
Janssen: Consultant, Investigator and Scientific Advisor, Consulting fee and Research grant
Merck : Investigator and Scientific Advisor, Research grant
Pfizer: Steering Committe, Consulting fee
Vertex: Investigator and Scientific Advisor, Consulting fee and Research grant

R. Nahass, Merck: Investigator, Research support and Speaker honorarium
Gilead: Investigator, Consulting fee and Research support
BMS: Investigator, Research support
Janssen: Investigator, Research support
Vertex: Speaker's Bureau, Speaker honorarium

R. Wasserman, None

See more of: Pre-meeting Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.